ALDX Quote, Financials, Valuation and Earnings

Akebia Therapeutics has a net margin of -- compared to Aldeyra Therapeutics's net margin of -53.54%. Aldeyra Therapeutics's return on equity of -- beat Akebia Therapeutics's return on equity of --.

Aldeyra Therapeutics has a consensus price target of --, signalling upside risk potential of 105.76%. On the other hand Akebia Therapeutics has an analysts' consensus of -- which suggests that it could grow by 199.73%. Given that Akebia Therapeutics has higher upside potential than Aldeyra Therapeutics, analysts believe Akebia Therapeutics is more attractive than Aldeyra Therapeutics.

Aldeyra Therapeutics has a beta of 1.342, which suggesting that the stock is 34.234% more volatile than S&P 500. In comparison Akebia Therapeutics has a beta of 0.699, suggesting its less volatile than the S&P 500 by 30.101%.

Aldeyra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akebia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics pays -- of its earnings as a dividend. Akebia Therapeutics pays out -- of its earnings as a dividend.

Aldeyra Therapeutics quarterly revenues are --, which are smaller than Akebia Therapeutics quarterly revenues of $37.4M. Aldeyra Therapeutics's net income of -$15.1M is higher than Akebia Therapeutics's net income of -$20M. Notably, Aldeyra Therapeutics's price-to-earnings ratio is -- while Akebia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics is -- versus 2.20x for Akebia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

iBio has a net margin of -- compared to Aldeyra Therapeutics's net margin of -4444.57%. Aldeyra Therapeutics's return on equity of -- beat iBio's return on equity of -148.3%.

Aldeyra Therapeutics has a consensus price target of --, signalling upside risk potential of 105.76%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that Aldeyra Therapeutics has higher upside potential than iBio, analysts believe Aldeyra Therapeutics is more attractive than iBio.

Aldeyra Therapeutics has a beta of 1.342, which suggesting that the stock is 34.234% more volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

Aldeyra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Aldeyra Therapeutics quarterly revenues are --, which are smaller than iBio quarterly revenues of $175K. Aldeyra Therapeutics's net income of -$15.1M is lower than iBio's net income of -$4M. Notably, Aldeyra Therapeutics's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Aldeyra Therapeutics's net margin of -49.65%. Aldeyra Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Aldeyra Therapeutics has a consensus price target of --, signalling upside risk potential of 105.76%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Aldeyra Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Aldeyra Therapeutics.

Aldeyra Therapeutics has a beta of 1.342, which suggesting that the stock is 34.234% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Aldeyra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Aldeyra Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Aldeyra Therapeutics's net income of -$15.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Aldeyra Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Aldeyra Therapeutics's net margin of -2357.27%. Aldeyra Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

Aldeyra Therapeutics has a consensus price target of --, signalling upside risk potential of 105.76%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Aldeyra Therapeutics, analysts believe Palatin Technologies is more attractive than Aldeyra Therapeutics.

Aldeyra Therapeutics has a beta of 1.342, which suggesting that the stock is 34.234% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Aldeyra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Aldeyra Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Aldeyra Therapeutics's net income of -$15.1M is lower than Palatin Technologies's net income of -$7.8M. Notably, Aldeyra Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.